Crohn's Disease

A new integrative model demonstrated “strong predictive performance” in identifying future risk for Crohn’s disease development among healthy first-degree relatives of patients with CD, according to a researcher.

The FDA has approved subcutaneous and IV formulations of the Stelara biosimilar Otulfi for Crohn’s disease, ulcerative colitis and all other indications approved for the reference product, according to a press release from Fresenius Kabi.

A 65-year-old woman presents for evaluation of a 6-month history of chronic diarrhea. She has generally been healthy throughout her life.

The treatment sequence of vedolizumab to adalimumab resulted in the lowest overall incidences of hospitalization and surgery in both Crohn’s disease and ulcerative colitis compared with other biologic treatment sequences, research showed.

Following a July boom in game-changing FDA approvals for gastroenterology, including the first blood test for colorectal cancer, the agency has succumbed to the summer lull with only three approvals for GI to close out the season.

Early endoscopic improvement after Skyrizi induction was associated with fewer Crohn’s disease-related hospitalizations and surgeries through 52 weeks of maintenance in patients with moderately to severely active disease, research showed.

Initiation of biological therapy within the first year of Crohn’s disease diagnosis was associated with a higher rate of transmural healing, as well as decreased risk for bowel damage progression, surgery and therapy escalation.